✦ LIBER ✦

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

✍ Scribed by Finckh, A; Ciurea, A; Brulhart, L; Moller, B; Walker, U A; Courvoisier, D; Kyburz, D; Dudler, J; Gabay, C

Book ID: 127325062
Publisher: BMJ Publishing Group
Year: 2009
Tongue: English
Weight: 614 KB
Volume: 69
Category: Article
ISSN: 0003-4967
DOI: 10.1136/ard.2008.105064

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS38 COST-EFFECTIVENESS OF RITUXIMAB VE

PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO

✍ F Carlos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PMS39 COST-EFFECTIVENESS OF RITUXIMAB VE

PMS39 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN COSTA RICA

✍ F Carlos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Comparative effectiveness of switching t

Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study

✍ Gomez-Reino, J. J.; Maneiro, J. R.; Ruiz, J.; Rosello, R.; Sanmarti, R.; Romero, 📂 Article 📅 2012 🏛 BMJ Publishing Group 🌐 English ⚖ 107 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt